Linking AI to materials discovery across biology and manufacturing

D. -M. Mei, K. Acharya, C. M. Adhikari, M. Adhikari, S. Aryal, B. V. Benson, K. Bhatta, S. Bhattarai, N. Budhathoki, A. M. Castillo, D. Chakraborty, S. Chhetri, S. Choudhury, T. A. Chowdhury, R. D. Cruz, B. Cui, S. Dhital, K. -M. Dong, R. Gapuz, A. Ghasemi, E. Z. Gnimpieba, B. D. S. Gurung, H. A. Hashim, R. I. Harry, K. -E. Hasin, M. K. Hassanzadeh, M. K. Jha, D. Kim, K. -C. Kong, B. Lama, A. Mahat, N. Maharjan, A. Majeed, J. Mammo, M. M. Masud, K. S. Moore, A. Nawaz, H. Oli, S. A. Panamaldeniya, L. Pandey, R. Pandey, Z. Peng, A. Prem, M. M. Rana, K. Rana Magar, R. Rizk, C. S. Tadi, L. -W. Wang, Y. Yang, G. -L. Yin, C. -X. Yu, D. Zeng, M. Zhou, Q. Zhou

Materials scientists need models that weigh composition, structure, biological effects, and safety all at once—but materials and biomedical databases rarely talk to each other. AIMBio proposes a framework that ties these data sources together through a governance-aware AI layer, using uncertainty-aware machine learning and human-guided active learning to navigate competing constraints. The authors sketch governance requirements, metadata standards, and risk tiers, then demonstrate the concept with a pilot automating nanomaterial design for drug delivery. This is infrastructure for early-stage discovery, not clinical tools, but it charts a path toward reproducible, auditable AI-driven materials research.